Calcitonin gene-related peptide antagonizes the protective effect of adrenomedullin on histamine-induced bronchoconstriction. 1996

H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
First Department of Internal Medicine, Osaka City University Medical School, Japan.

1. In the present study the possible relationship between adrenomedullin (AM) and calcitonin gene-related peptide (CGRP) in the regulation of airway functions in anaesthetized guinea-pigs was examined in vivo. 2. We found that AM significantly inhibited histamine-induced bronchoconstriction in a dose-dependent manner. CGRP or the CGRP receptor antagonist (CGRP [8-37]) alone did not affect pulmonary resistance and pretreatment with CGRP or CGRP [8-37] did not significantly affect histamine-induced bronchoconstriction. However, AM-induced bronchoprotection was significantly inhibited by pretreatment with CGRP or CGRP [8-37] in a dose-dependent manner. 3. It is therefore possible that CGRP may be competitive, at least in part, with binding sites of AM in the guinea-pig airway. Exogenous AM may be useful for the management of bronchial asthma, not only as a potent bronchodilator, but also as a functional antagonist of CGRP.

UI MeSH Term Description Entries
D008297 Male Males
D008916 Miotics Agents causing contraction of the pupil of the eye. Some sources use the term miotics only for the parasympathomimetics but any drug used to induce miosis is included here. Miotic Effect,Miotic Effects,Effect, Miotic,Effects, Miotic
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001985 Bronchial Provocation Tests Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma. Allergen Bronchial Provocation Tests,Allergen Challenge, Endobronchial,Antigen Bronchial Provocation Tests,Bronchial Allergen Challenge,Bronchial Challenge Tests,Inhalation Provocation Tests,Provocation Tests, Bronchial,Endobronchial Challenge Tests,Allergen Challenge, Bronchial,Allergen Challenges, Bronchial,Allergen Challenges, Endobronchial,Bronchial Allergen Challenges,Bronchial Challenge Test,Bronchial Provocation Test,Challenge Test, Bronchial,Challenge Test, Endobronchial,Challenge Tests, Bronchial,Challenge Tests, Endobronchial,Challenge, Bronchial Allergen,Challenge, Endobronchial Allergen,Challenges, Bronchial Allergen,Challenges, Endobronchial Allergen,Endobronchial Allergen Challenge,Endobronchial Allergen Challenges,Endobronchial Challenge Test,Inhalation Provocation Test,Provocation Test, Bronchial,Provocation Test, Inhalation,Provocation Tests, Inhalation,Test, Bronchial Challenge,Test, Bronchial Provocation,Test, Endobronchial Challenge,Test, Inhalation Provocation,Tests, Bronchial Challenge,Tests, Bronchial Provocation,Tests, Endobronchial Challenge,Tests, Inhalation Provocation
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006633 Histamine Antagonists Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. Classical antihistaminics block the histamine H1 receptors only. Antihistamine,Antihistamines,Histamine Antagonist,Antagonist, Histamine,Antagonists, Histamine
D000403 Airway Resistance Physiologically, the opposition to flow of air caused by the forces of friction. As a part of pulmonary function testing, it is the ratio of driving pressure to the rate of air flow. Airway Resistances,Resistance, Airway,Resistances, Airway
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
August 1999, Molecular endocrinology (Baltimore, Md.),
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
March 1998, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
October 2009, Maturitas,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
January 1997, Critical reviews in neurobiology,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
July 1995, Canadian journal of physiology and pharmacology,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
March 2001, British journal of pharmacology,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
August 1990, International journal of clinical pharmacology, therapy, and toxicology,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
May 2001, Brain research bulletin,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
July 2004, Physiological reviews,
H Kanazawa, and T Kawaguchi, and H Kamoi, and T Fujii, and S Kudoh, and K Hirata, and N Kurihara, and J Yoshikawa
January 2020, Biological & pharmaceutical bulletin,
Copied contents to your clipboard!